Branded Medicine

Tablet - Suspension
VOMETA tablet
Each tablet contains:
  • Domperidone 10 mg

VOMETA suspension
Each teaspoonful (5 ml) contains:

  • Domperidone 5 mg
Domperidone is a benzimidazole derivatives with prokinetic and antiemetic effects, with the latter effect very similar to metoclopramide. Extrapyramidal reactions are rare as domperidone generally does not cross the blood brain barrier. Oral administration prolongs the contraction of anthrum and duodenum, increase gastric emptying and pressure of lower oesophagus sphincter. There is no side effect to gastric secretion.
  • Dyspepsia syndrome, which is accompanied by delayed gastric emptying, esophageal reflux and esophagitis:
    • pigastric and abdominal fullness.
    • Nausea and vomiting.
    • Heartburn with/without regurgitation.
  • Nausea and vomiting due to various causes:
    • astrointestinal intolerance due to anti-cancer chemotherapy, digitalis, L-dopa and others including radiotherapy.
    • bdominal organs, gastrointestinal hepatobiliary, peritoneal and renal pathology.
    • ediatric pathology due to functional disorders (plyoropasm, cyclic vomiting) or organic disorders, intoxication by infection, dietary or acetonemia.

Patients with intolerance to this drug.

Domperidone cannot be administered if gastric motility causes bleeding, mechanical obstruction or gastrointestinal perforation. Domperidone is also contraindicated in patients with prolactinoma and tumor hypohyloma which produce prolactin.

Domperidone rarely causes central nervous symptoms, including extapyramidal symptoms, because of its poor penetration to the blood-brain barrier. Domperidone can induce hyperprolactinemia in many patients, resulting in breast tenderness and enlargement, galactorrhea and gynecomastia. Domperidone rarely causes allergic reaction like rash and urticaria.
:: DOSAGE ::
  • Chronic dyspepsia
    Adults : 10 mg (1 tablet) 3 times daily, 15-30 minutes before meals if necessary it can be repeated before retiring.
    Children: 2.5 mg per 10 kg of body weight, 3 times daily, before melas, if necessary it can be repeated before retiring.
  • Nausea and Vomiting
    Adults : 10-20 mg (1 tablet), 3-4 times daily, before meals and before retiring.
    Children: 2.5-5 mg per 10 kg of body weight, 3-4 times daily before meals and before retiring.
  • If antacid were administered concomitantly with anti secretion drug, this must be given after meals and not administered concomitantly with domperidone.
  • omperidone is not recommended for long term treatment.
  • sed with caution in patients with hepatic impairments.
  • ot recommended in pregnant womn or nursing mothers.

The symptoms caused by overdosage of this drug: sleepiness, disorientation, extrapyramidal reaction especially in children. Anticholinergic effect, can help to control extrapyramidal reactions.

There is no specific antidote for overdosage, but activated charcoal can be given and it is better to observe and give symptomatic treatment.

  • Administration of anticholinergic concomitantly can antagonize antidyspepsia effects of domperidone. Do not administered concomitantly antacids with domperidone because they will decrease the domperidone bioavailability. Theoretically gastrokinetic effects of domperidone will disturb the absorption of oral drug when administered concomitantly, especially 'sustained release' or 'enteric coated' drug. But in patients generally used digoxin or paracetamol administered concomitantly with domperidone did not effect blood concentration of this drug. Domperidone can be administered concomitantly with:
  • eurologic drugs, with have no potentiation of effects.
  • gonist dopaminergic drugs (bromocriptine, L-dopa), where the peripheral effects e.g.: gastric disorders, nausea and vomiting can be decreased without reducing the central activity.
:: PRESENTATION and Reg. No ::

VOMETA tablet : Box of 10 blisters @ 10 tablets. Reg. No.: DKL9405013610A1

VOMETA suspension : Bottle content @ 60 ml. Reg. No.: DKL9405013733A1